<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318551</url>
  </required_header>
  <id_info>
    <org_study_id>15557</org_study_id>
    <secondary_id>2011-000055-16</secondary_id>
    <nct_id>NCT01318551</nct_id>
  </id_info>
  <brief_title>Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects</brief_title>
  <official_title>Investigation of Pharmacokinetics, Safety, Tolerability, and Pharmacodynamic Effects of BAY85-3934 in Male and Female Subjects With Renal Impairment and in Age- and Weight-matched Healthy Subjects Following a Single Oral Dose of 20 mg and 40 mg (Optional) BAY 85-3934 Administered as Tablets in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single&#xD;
      dose group stratified study in renal impaired and healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2011</start_date>
  <completion_date type="Actual">August 14, 2014</completion_date>
  <primary_completion_date type="Actual">September 5, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of BAY85-3934</measure>
    <time_frame>Day 0 to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of BAY85-3934</measure>
    <time_frame>Day 0 to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized area under the plasma concentration-time curve (AUCnorm) of BAY85-3934</measure>
    <time_frame>Day 0 to day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose- and body weight-normalised Cmax (Cmax-norm) of BAY85-3934</measure>
    <time_frame>Day 0 to day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY85-3934</intervention_name>
    <description>single dose, 20 mg</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY85-3934</intervention_name>
    <description>single dose, 40 mg (optional)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY85-3934</intervention_name>
    <description>single dose, 80 mg (optional)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The informed consent must be signed before any study-specific tests or procedures are&#xD;
             done.&#xD;
&#xD;
          -  Female subjects with no child-bearing potential (postmenopausal women with 12 months&#xD;
             of spontaneous amenorrhea or with 6 months of spontaneous amenorrhea and serum FSH&#xD;
             concentrations &gt;30 mIU/mL, women with 6 weeks post bilateral ovariectomy, woman with&#xD;
             bilateral tubal ligation, and women with hysterectomy).&#xD;
&#xD;
          -  Male subjects who agree to use 2 forms of effective contraception during the study and&#xD;
             for 12 weeks after receiving the study drug. This must include a condom with&#xD;
             spermicide gel for 21 days after drug administration.&#xD;
&#xD;
          -  Male subjects who agree not to act as sperm donors for 12 weeks after dosing.&#xD;
&#xD;
          -  Age: ≥18 and ≤79 years at the pre-study visit.&#xD;
&#xD;
          -  Body mass index (BMI): ≥18 and ≤34 kg/m2.&#xD;
&#xD;
          -  Ethnicity: white.&#xD;
&#xD;
          -  • Subjects participating in this trial and having received 20 mg BAY 85 3934 are&#xD;
             encouraged to participate in the following optionally 40 mg and 80 mg study parts.&#xD;
&#xD;
          -  Ability to understand and follow study-related instructions.&#xD;
&#xD;
          -  For subjects with renal impairment:&#xD;
&#xD;
               -  In diseased subjects: CLCR &lt;90 mL/min determined from a serum creatinine control.&#xD;
&#xD;
               -  In diseased subjects: stable renal disease, ie a serum creatinine value&#xD;
                  determined at least 3 months before the pre-study visit during routine&#xD;
                  diagnostics independently of the study should not vary by more than 20% from the&#xD;
                  serum creatinine value determined at the pre-study visit.&#xD;
&#xD;
          -  For healthy subjects:&#xD;
&#xD;
               -  Mean age and body weight in Group 1 or Group 6 or Group 11 (control group,&#xD;
                  healthy subjects) and Groups 2 to 5 and Groups 7 to 10 and Groups 12 to 15 should&#xD;
                  not vary by more than +10 years and +10 kg, respectively..&#xD;
&#xD;
               -  In diseased subjects: CLCR ≥90 mL/min determined from a serum creatinine control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical trial during the preceding 3 months for&#xD;
             multiple-dose studies and 1 month for single-dose studies; (final examination from&#xD;
             previous study to first treatment of new study).&#xD;
&#xD;
          -  Exclusion periods from other studies or simultaneous participation in other clinical&#xD;
             studies.&#xD;
&#xD;
          -  Donation of &gt;100 mL of blood within 4 weeks before the first study drug administration&#xD;
             or &gt;500 mL in the preceding 3 months.&#xD;
&#xD;
          -  Medical disorder that would impair the subject's ability to complete the study in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  Severe infection or any clinically significant illness within 4 weeks prior to dosing.&#xD;
&#xD;
          -  Known hypersensitivity to the study drugs (active substances, or excipients of the&#xD;
             preparations).&#xD;
&#xD;
          -  Known severe allergies, non-allergic drug reactions, or multiple drug allergies.&#xD;
&#xD;
          -  Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus&#xD;
             antibodies (HCV Ab), human immune deficiency virus antibodies (HIV 1/2 Ab).&#xD;
&#xD;
          -  Regular use of recreational drugs, eg carnitine products, anabolics.&#xD;
&#xD;
          -  Regular daily consumption of ≥ 0.5 L of usual beer or the equivalent quantity of&#xD;
             approximately 20 g of alcohol in another form.&#xD;
&#xD;
          -  Suspicion of drug or alcohol abuse.&#xD;
&#xD;
          -  Positive urine drug screening.&#xD;
&#xD;
          -  Regular daily consumption of &gt;25 cigarettes.&#xD;
&#xD;
          -  Criteria which in the opinion of the investigator preclude participation for&#xD;
             scientific reasons, for reasons of compliance, or for reasons of the subject's safety.&#xD;
&#xD;
          -  Use of medication within the 2 weeks preceding the study which could interfere with&#xD;
             the investigational product.&#xD;
&#xD;
          -  For subjects with renal impairment:&#xD;
&#xD;
               -  Acute renal failure.&#xD;
&#xD;
               -  Acute nephritis.&#xD;
&#xD;
               -  Nephrotic syndrome.&#xD;
&#xD;
               -  Any organ transplant &lt; 1 year before participation in this study.&#xD;
&#xD;
               -  Failure of any other major organ system other than the kidney.&#xD;
&#xD;
               -  Relevant impairment in liver function of by option of the investigator.&#xD;
&#xD;
               -  Pre-existing diseases for which it can be assumed that the absorption of the&#xD;
                  study drugs will not be normal (ie relevant malabsorption, chronic diarrhea).&#xD;
&#xD;
               -  Diastolic blood pressure (DBP) &gt;100 mmHg and/or systolic blood pressure (SBP)&#xD;
                  &gt;180 mmHg (at the pre-study examination; readings taken at the end of the dosing&#xD;
                  interval of antihypertensive medication, if any).&#xD;
&#xD;
               -  Heart rate &lt;45 or &gt;100 BPM for subject aged 18 to ≤50 years and &lt;55 or &gt;110 BPM&#xD;
                  for subject aged &gt;50 to ≤79 years at screening visit.&#xD;
&#xD;
               -  Significant uncorrected rhythm or conduction disturbances such as a second- or&#xD;
                  third-degree AV block without a cardiac pacemaker or episodes of sustained&#xD;
                  ventricular tachycardia, or by option of the investigator.&#xD;
&#xD;
               -  Diagnosed malignancy within the past 5 years.&#xD;
&#xD;
               -  Psychiatric disorders which may disable the subjects to consent.&#xD;
&#xD;
               -  Change in chronic medications &lt;4 weeks prior to dosing.&#xD;
&#xD;
               -  Concomitant use of any medication except medications necessary for the treatment&#xD;
                  of the kidney disease or related complications.&#xD;
&#xD;
          -  For healthy subjects&#xD;
&#xD;
               -  Subjects with conspicuous findings in medical history or pre-study examination by&#xD;
                  option of the investigator.&#xD;
&#xD;
               -  A history of relevant diseases of vital organs, of the central nervous system or&#xD;
                  other organs.&#xD;
&#xD;
               -  Pre-existing diseases for which it can be assumed that the absorption,&#xD;
                  distribution, metabolism, elimination and effects of the study drugs will not be&#xD;
                  normal.&#xD;
&#xD;
               -  Systolic blood pressure &lt;100 mmHg or &gt;145 mmHg.&#xD;
&#xD;
               -  Diastolic blood pressure &gt;95 mmHg.&#xD;
&#xD;
               -  Heart rate &lt;45 or &gt;95 BPM for subject aged 18 to ≤50 years and &lt;55 or &gt;95 BPM for&#xD;
                  subject aged &gt;50 to ≤79 years at screening visit.&#xD;
&#xD;
               -  Clinically relevant findings in the ECG such as a second- or third-degree AV&#xD;
                  block, clinically relevant prolongation of the QRS complex &gt;120 ms or of the QTc&#xD;
                  interval &gt;450 ms for men and &gt;470 ms for women of by option of the investigator.&#xD;
&#xD;
               -  Clinically relevant deviations of the screened laboratory parameters in clinical&#xD;
                  chemistry, hematology, or urinalysis from reference range of by option of the&#xD;
                  investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

